Last reviewed · How we verify

NCT03334721

Gabapentin for Bipolar & Cannabis Use Disorders

Completed Phase 2 Results posted Last updated 13 November 2020
What this trial tests

Phase 2 trial testing Gabapentin in Bipolar I Disorder in 23 participants. Completed in 1 July 2019.

Timeline
1 October 2017
Primary endpoint
1 July 2019
1 July 2019

Quick facts

Lead sponsorMedical University of South Carolina
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposebasic science
Enrollment23
Start date1 October 2017
Primary completion1 July 2019
Estimated completion1 July 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of South Carolina

Who can join

Adults 18 to 65, any sex, with Bipolar I Disorder or Bipolar II Disorder. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Prefrontal GABA Concentrations Through Proton Magnetic Resonance Spectroscopy Primary · Day 5 of each experimental condition

Concentrations of GABA, normalized to water and corrected for CSF%, in dorsal anterior cingulate measured via Proton Magnetic Resonance Spectroscopy.

GABA (randomization order 1, gabapentin 1st)
GroupValue95% CI
Gabapentin2.625± 0.324
Placebo Oral Capsule2.696± 0.313
GABA (randomization order 2, placebo 1st)
GroupValue95% CI
Gabapentin2.609± 0.290
Placebo Oral Capsule2.720± 0.248

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events were collected over a total of 4 visits (Med 1, MRI 1, Med 2, MRI 2) for each participant; 2-weeks.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Gabapentin
Serious: 0/23 (0%)
Deaths: 0/23
Placebo Oral Capsule
Serious: 0/22 (0%)
Deaths: 0/22
Other adverse events (12 terms — click to expand)

ReactionSystemGabapentinPlacebo Oral Capsule
FatigueGeneral disorders
DizzinessNervous system disorders
HeadacheNervous system disorders
NauseaGastrointestinal disorders
VomitingGastrointestinal disorders
DiarrheaGastrointestinal disorders
BlepharospasmEye disorders
Increased AppetiteMetabolism and nutrition disorders
SomnolenceNervous system disorders
Memory ImpairmentNervous system disorders
Abdominal PainMusculoskeletal and connective tissue disorders
InsomniaPsychiatric disorders

Data from ClinicalTrials.gov NCT03334721 adverse events section.

Sponsor's own description

The proposed 2-week, double-blind, crossover, proof of concept study aims to measure and manipulate core neurochemical (i.e., dysregulated brain GABA/glutamate homeostasis) and neurobehavioral (i.e., elevated impulsivity) dysfunctions characteristic of individuals with cannabis use disorder (CUD) and Bipolar Disorder (BD), using a medication that has been shown to increase cortical GABA (i.e., gabapentin) levels in past research, and to evaluate medication-related changes in response inhibition (go no-go) and cannabis cue reactivity functional Magnetic Resonance Imaging tasks, as well as cannabis use, mood symptoms (including anxiety and sleep), and impulsivity in individuals with CUD+BD.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders.
    Prisciandaro JJ, Mellick W, Squeglia LM, Hix S, et al · · 2022 · cited 15× · PMID 34390300 · DOI 10.1111/adb.13085

Verify or expand the search:

Other trials of Gabapentin

Trials testing the same drug.

Other recruiting trials for Bipolar I Disorder

Currently open trials in the same condition.

Other Medical University of South Carolina trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03334721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing